scholarly journals Detection and characterization of human high molecular weight B cell growth factor receptors on leukemic B cells in chronic lymphocytic leukemia.

1989 ◽  
Vol 84 (5) ◽  
pp. 1595-1608 ◽  
Author(s):  
F M Uckun ◽  
A S Fauci ◽  
M Chandan-Langlie ◽  
D E Myers ◽  
J L Ambrus
Keyword(s):  
Molecular Weight ◽  
B Cells ◽  
Growth Factor ◽  
Cell Growth ◽  
Chronic Lymphocytic Leukemia ◽  
B Cell ◽  
High Molecular Weight ◽  
Lymphocytic Leukemia ◽  
B Cell Growth Factor

scholarly journals Purification to homogeneity of a high molecular weight human B cell growth factor; demonstration of specific binding to activated B cells; and development of a monoclonal antibody to the factor.

1985 ◽  
Vol 162 (4) ◽  
pp. 1319-1335 ◽  
Author(s):  
J L Ambrus ◽  
C H Jurgensen ◽  
E J Brown ◽  
A S Fauci
Keyword(s):  
Molecular Weight ◽  
Monoclonal Antibody ◽  
B Cells ◽  
Growth Factor ◽  
Cell Growth ◽  
B Cell ◽  
High Molecular Weight ◽  
Sodium Dodecyl ◽  
Western Blots ◽  
B Cell Growth Factor

High molecular weight B cell growth factor (HMW-BCGF) produced by a T cell line was purified to homogeneity and demonstrated to bind specifically to activated human B cells. A monoclonal antibody to HMW-BCGF was developed that (a) specifically inhibited the activity of HMW-BCGF in enhancing B cell proliferation, (b) specifically bound to HMW-BCGF in Western blots, (c) specifically absorbed HMW-BCGF activity from culture supernatants, and (d) specifically absorbed an internally labeled protein from T-ALL supernatant which comigrates with HMW-BCGF on sodium dodecyl sulfate-polyacrylamide gels. This antibody should help in cloning the gene for HMW-BCGF and further exploring the physiologic roles of HMW-BCGF.

Proliferation of B Cells from Chronic Lymphocytic Leukemia Is Selectively Promoted by B Cell Growth Factor

1989 ◽  
Vol 81 (2) ◽  
pp. 91-97 ◽  
Author(s):  
Melchor Alvarez-Mon ◽  
Antonio de la Hera ◽  
Maria Luisa Gaspar ◽  
Alberto Orfao ◽  
Juan Casas ◽  
...  
Keyword(s):  
B Cells ◽  
Growth Factor ◽  
Cell Growth ◽  
Chronic Lymphocytic Leukemia ◽  
B Cell ◽  
Lymphocytic Leukemia ◽  
B Cell Growth Factor

scholarly journals Functional heterogeneity of B-CLL lymphocytes: dissociated responsiveness to growth factors and distinct requirements for a first activation signal

Blood ◽  
1987 ◽  
Vol 70 (4) ◽  
pp. 1105-1110
Author(s):  
S Karray ◽  
H Merle-Beral ◽  
A Vazquez ◽  
JP Gerard ◽  
P Debre ◽  
...  
Keyword(s):  
Molecular Weight ◽  
Growth Factors ◽  
Growth Factor ◽  
Chronic Lymphocytic Leukemia ◽  
B Cell ◽  
B Lymphocytes ◽  
Lymphocytic Leukemia ◽  
Functional Heterogeneity ◽  
B Cell Growth Factor ◽  
Directed Growth

We studied the effects of B cell directed growth factors on B lymphocytes from 11 patients with chronic lymphocytic leukemia (B-CLL). B-CLL lymphocytes were costimulated with anti-mu antibody (Ab) and with three growth factor preparations: recombinant IL2, B cell growth factor (BCGF) (20 kiloDalton (kD) BCGF) and a high molecular weight BCGF (50 kD BCGF). IL2 was the more active factor (in six of 11 patients). The effect of IL2 was dependent on a costimulation with anti-mu Ab or occurred independently of anti-mu Ab, according to the patients. This pattern of reactivity did not correlate with the presence or absence of the IL2 receptor (IL2-R) molecule on fresh B-CLL lymphocytes. Five patients responded to the 20 kD BCGF. Although four of them were also strong responders to IL2, one strongly responded to the 20 kD BCGF and did not respond to IL2. Only one patient responded to the 50 kD BCGF. When an anti-IL2-R Ab was introduced into the culture, only the responsiveness to IL2 was abolished: thus both 20 kD and 50 kD BCGFs activate B-CLL lymphocytes independently of the IL2-R. These results show that several B cell directed growth factors can act independently to support the proliferation of B-CLL lymphocytes.

Different human B cell subsets respond to interleukin 2 and to a high molecular weight B cell growth factor (BCGF)

1986 ◽  
Vol 16 (12) ◽  
pp. 1503-1507 ◽  
Author(s):  
Aime Vazquez ◽  
Jean-Philipe Gerard ◽  
Daniel Olive ◽  
Marie-Thérèse Auffredou ◽  
Bernard Dugas ◽  
...  
Keyword(s):  
Molecular Weight ◽  
Growth Factor ◽  
Cell Growth ◽  
B Cell ◽  
High Molecular Weight ◽  
Interleukin 2 ◽  
B Cell Growth Factor ◽  
B Cell Subsets ◽  
Human B Cell

B cell hyperactivity in systemic lupus erythematosus: selectively enhanced responsiveness to a high molecular weight B cell growth factor

1986 ◽  
Vol 16 (10) ◽  
pp. 1251-1256 ◽  
Author(s):  
Jean-François Delfraissy ◽  
Christine Wallon ◽  
Aimé Vazquez ◽  
Bernard Dugas ◽  
Jean Dormont ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Molecular Weight ◽  
Growth Factor ◽  
Cell Growth ◽  
B Cell ◽  
High Molecular Weight ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
B Cell Growth Factor

scholarly journals Identification of a cDNA for a human high-molecular-weight B-cell growth factor.

1993 ◽  
Vol 90 (13) ◽  
pp. 6330-6334 ◽  
Author(s):  
J. L. Ambrus ◽  
J. Pippin ◽  
A. Joseph ◽  
C. Xu ◽  
D. Blumenthal ◽  
...  
Keyword(s):  
Molecular Weight ◽  
Growth Factor ◽  
Cell Growth ◽  
B Cell ◽  
High Molecular Weight ◽  
B Cell Growth Factor

scholarly journals Functional heterogeneity of B-CLL lymphocytes: dissociated responsiveness to growth factors and distinct requirements for a first activation signal

Blood ◽  
1987 ◽  
Vol 70 (4) ◽  
pp. 1105-1110 ◽  
Author(s):  
S Karray ◽  
H Merle-Beral ◽  
A Vazquez ◽  
JP Gerard ◽  
P Debre ◽  
...  
Keyword(s):  
Molecular Weight ◽  
Growth Factors ◽  
Growth Factor ◽  
Chronic Lymphocytic Leukemia ◽  
B Cell ◽  
B Lymphocytes ◽  
Lymphocytic Leukemia ◽  
Functional Heterogeneity ◽  
B Cell Growth Factor ◽  
Directed Growth

Abstract We studied the effects of B cell directed growth factors on B lymphocytes from 11 patients with chronic lymphocytic leukemia (B-CLL). B-CLL lymphocytes were costimulated with anti-mu antibody (Ab) and with three growth factor preparations: recombinant IL2, B cell growth factor (BCGF) (20 kiloDalton (kD) BCGF) and a high molecular weight BCGF (50 kD BCGF). IL2 was the more active factor (in six of 11 patients). The effect of IL2 was dependent on a costimulation with anti-mu Ab or occurred independently of anti-mu Ab, according to the patients. This pattern of reactivity did not correlate with the presence or absence of the IL2 receptor (IL2-R) molecule on fresh B-CLL lymphocytes. Five patients responded to the 20 kD BCGF. Although four of them were also strong responders to IL2, one strongly responded to the 20 kD BCGF and did not respond to IL2. Only one patient responded to the 50 kD BCGF. When an anti-IL2-R Ab was introduced into the culture, only the responsiveness to IL2 was abolished: thus both 20 kD and 50 kD BCGFs activate B-CLL lymphocytes independently of the IL2-R. These results show that several B cell directed growth factors can act independently to support the proliferation of B-CLL lymphocytes.

scholarly journals B8.7 antigen is present on B-cell precursor acute lymphocytic leukemia. Correlation with the low molecular weight B-cell growth factor responsiveness of these cells

Blood ◽  
1990 ◽  
Vol 75 (4) ◽  
pp. 963-971 ◽  
Author(s):  
C Leprince ◽  
N Blumenfeld ◽  
G Flandrin ◽  
P Galanaud ◽  
F Sigaux ◽  
...  
Keyword(s):  
Molecular Weight ◽  
Growth Factor ◽  
Cell Growth ◽  
B Cell ◽  
Lymphocytic Leukemia ◽  
Low Molecular Weight ◽  
Dependent Manner ◽  
Cell Precursor ◽  
B Cell Growth Factor ◽  
Human B Cell

Abstract The purpose of this study was to analyze the expression of B8.7 antigen and its implication in the low molecular weight B-Cell growth factor (LMW BCGF) proliferative pathway at the early stages of the human B- cell differentiation. After an overnight incubation in culture medium of B-cell precursor acute lymphoblastic leukemias (ALL), we demonstrated the presence of B8.7 antigen in 18 of 25 cases (72%). Such an incubation also induced a significant increase in the LMW BCGF responsiveness of ALL cells (P less than 0.03). In addition, we showed a significant correlation between B8.7 expression and the ability of pre-B ALL cells to respond to LMW BCGF. As previously described for normal B cells, the anti-B8.7 monoclonal antibody inhibited the LMW BCGF-dependent proliferation of pre-B ALL cells in a dose-dependent manner. These data indicate that B8.7 antigen is expressed and may be functionally related to the LMW BCGF pathway at the pre-B cell stages of differentiation. These results also suggest that human B-cell precursor ALL are not only phenotypically similar to their normal B lymphocyte counterparts, but are also sensitive to the same immunoregulatory cytokines that control normal cell growth.

Sign in / Sign up

Export Citation Format

Share Document